CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Selexipag

Last Updated: February 16, 2016
Result type: Reports
Project Number: SR0482-000
Product Line: Common Drug Review

Generic Name: Selexipag

Brand Name: Uptravi

Manufacturer: Actelion Pharmaceuticals Canada Inc.

Indications: Pulmonary arterial hypertension (WHO class II and III)

Submission Type: New

Project Status: Complete

Date Recommendation Issued: October 28, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions